NCT06264778 2024-02-20
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
Shandong University
Phase 3 Unknown
Clinical Trials
12 trialsNCT05876806 2023-11-30
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Seoul St. Mary's Hospital
Phase 2 Unknown
NCT05182931 2023-10-31
I-FIRST
Olivia Newton-John Cancer Research Institute
Phase 2 Unknown
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT04619316 2023-06-22
ERRITI
University Hospital, Essen
Phase 2 Unknown
NCT03668431 2022-06-27
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT05171374 2022-06-01
RATIONALE
MelanomaPRO, Russia
Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown
NCT04554680 2021-03-05
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
National University Hospital, Singapore
Phase 2 Unknown
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT02625337 2017-09-15
IMPemBra
The Netherlands Cancer Institute
Phase 2 Unknown